Daiichi Sankyo Company, Limited

4568.T
Drug Manufacturers - General
2026/02/17 Updated
Market Cap: $35.8B (¥5.5T)
Stock Price: $19.33 (¥2,955)
Exchange Rate: 1 USD = ¥152.91

Notice Regarding the Status of Treasury Stock Acquisitions

From January 1 to January 31, 2026, Daiichi Sankyo Company, Limited acquired 3,403,600 shares of the Company’s common stock at a total cost of 9,999,246,950 yen.

Importance:
Page Updated: February 2, 2026
IR Disclosure Date: February 2, 2026

Key Figures

  • Number of Shares Acquired: 3,403,600 shares (January 1 to January 31, 2026)
  • Total Acquisition Cost: 9,999,246,950 yen (same period)
  • Board Resolution Acquisition Cap: 80,000,000 shares
  • Board Resolution Acquisition Cost Cap: 200,000,000,000 yen
  • Acquisition Period Cap: May 1, 2025 – March 24, 2026

AI要約

Overview of Treasury Stock Acquisition

Daiichi Sankyo Company, Limited acquired 3,403,600 shares of its common stock during the period from January 1 to January 31, 2026, pursuant to the provisions of Article 165, Paragraph 2 of the Companies Act. The total acquisition cost amounted to 9,999,246,950 yen. The acquisition method was market purchase on the Tokyo Stock Exchange.

Acquisition Status Based on Board Resolution

The board resolution dated April 25, 2025, set the acquisition cap at 80 million shares, the acquisition cost limit at 200 billion yen, and the acquisition period from May 1, 2025, to March 24, 2026. As of January 31, 2026, the cumulative number of shares acquired is 3,403,600, with a cumulative acquisition cost of 9,999,246,950 yen.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.